Loading clinical trials...
Loading clinical trials...
Induction of SARS-CoV-2 Spike Glycoprotein Antibodies in Saliva and Plasma in Response to a COVID-19 Infection, Systemic COVID-19 Vaccination, and the Combination of COVID-19 and Vaccination
Conditions
Interventions
Blood- and saliva tests
Start Date
April 1, 2021
Primary Completion Date
May 1, 2021
Completion Date
March 15, 2024
Last Updated
April 13, 2021
NCT04525716
NCT03188796
NCT06355232
NCT05191420
NCT04611243
NCT04678193
Lead Sponsor
Lenanrt Friis-Hansen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions